Professional Semaglutide and Tirzepatide treatment programs with comprehensive telehealth consultations and ongoing support.
Semaglutide is an injectable medication that when used with a healthy diet and regular exercise can help individuals with known heart disease and/or obesity/overweight reduce the risk of major cardiovascular events such as heart attack, stroke, and even death.
Important: Semaglutide is the same active ingredient found in brand name medications such as Ozempic® and Wegovy®.
Semaglutide is a GLP-1 (glucagon-like peptide). This hormone is released by the gut and stimulates the pancreas to release insulin. This release of insulin removes glucose (sugar) from the blood and into cells for energy. GLP-1 also interacts with the brain to reduce appetite and increase the feeling of fullness. This helps reduce calorie intake which results in weight loss.
Comprehensive telehealth evaluation to determine if semaglutide is right for you.
Medication and supplies shipped directly to your home with detailed instructions.
Self-administered weekly injections using provided supplies and guidance.
Regular follow-up consultations to monitor progress and adjust treatment.
Clinical studies show average weight loss of 15-20% of body weight when combined with lifestyle changes
Reduces risk of major cardiovascular events including heart attack and stroke
Significantly reduces appetite and increases feeling of fullness, making portion control easier
Helps regulate blood glucose levels and improves insulin sensitivity
Decreases food cravings and helps break unhealthy eating patterns
All consultations via telehealth with medication delivered to your door
Tirzepatide is a next-generation injectable weight loss medication that targets two key hormones — GLP-1 and GIP — for superior results. It is the same active ingredient found in brand name medications such as Mounjaro® and Zepbound®.
Why Tirzepatide? Clinical studies show Tirzepatide produces greater weight loss than Semaglutide alone, with an average of 15-22% total body weight loss. Its dual-action mechanism makes it the most effective GLP-1 medication available today.
Unlike Semaglutide which targets only GLP-1, Tirzepatide activates both GLP-1 and GIP receptors. This dual mechanism enhances insulin secretion, suppresses appetite more effectively, and improves how your body processes fat and sugar. The result is faster, more significant weight loss with improved metabolic health.
Targets both GLP-1 and GIP receptors for enhanced weight loss results
Average 15-22% body weight loss — significantly more than single-action medications
Many patients report fewer GI side effects compared to GLP-1-only medications
Patients often see noticeable results within the first few weeks of treatment
Both are proven weight loss medications. Here's how they compare.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Avg. Weight Loss | 10–15% body weight | 15–22% body weight |
| Brand Equivalents | Ozempic®, Wegovy® | Mounjaro®, Zepbound® |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| GI Side Effects | Common (nausea, constipation) | Generally milder for many patients |
| Starting Price | $350 (initial visit) | $385 (30mg/3ml) |
Not sure which is right for you? Our providers will help you choose the best option during your telehealth consultation.
Get started for less than $117 a month!
Next-generation dual-action weight loss medication
No insurance is needed at all. Our services are self-pay for your convenience.
There is no upfront cost. You pay as you go with each treatment cycle.
Yes, every visit will be done via telehealth and consents will be sent for electronic signature after completion of visit.
Semaglutide is the active ingredient in brand name medications such as Ozempic and Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound.
Semaglutide targets one hormone (GLP-1), while Tirzepatide targets two (GLP-1 and GIP). This dual action typically results in greater weight loss — averaging 15-22% of body weight with Tirzepatide vs. 10-15% with Semaglutide.
Our providers will evaluate your health history, weight loss goals, and medical needs during your telehealth consultation to recommend the best option for you.
Schedule your initial consultation today and take the first step towards your health goals.